Sionna Therapeutics Secures $182 Million in Series C Funding to Revolutionize Cystic Fibrosis Treatment

Sionna Therapeutics is thrilled to announce the successful closure of a $182 million funding round that marks a significant milestone in our mission to revolutionize the treatment of cystic fibrosis (CF).

As a cutting-edge life sciences company, we are leveraging over a decade of extensive research dedicated to unraveling the complexities of genetic mutations associated with CF.

Our innovative approach revolves around the development of first-in-class small molecules that target a unique aspect of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, with the unprecedented goal of fully normalizing CFTR function.

This breakthrough could greatly benefit the vast majority of individuals living with CF, a condition that has long been a source of chronic health challenges.

The funds raised in this financing round will enable us to accelerate our research and development efforts, advancing our promising therapeutic candidates through clinical trials while expanding our team of talented researchers and scientists.

Additionally, this financial backing empowers us to scale up production capabilities, ensuring that we can meet the demands of future commercial distribution.

We deeply appreciate the support of our investors, who share our vision for a world where cystic fibrosis is no longer a life-limiting disease.

At Sionna Therapeutics, we are committed to forging ahead with our groundbreaking work, driven by a passion for bringing innovative treatments to those who need them most.

Stay tuned as we embark on this exciting journey toward transforming the lives of CF patients and providing hope for a healthier future.